Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

NCT05333458 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05333458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05333458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2022
Completion date
May 1, 2027
Enrollment
27 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced alveolar soft part sarcoma, advanced soft tissue sarcoma, metastatic alveolar soft part sarcoma, refractory alveolar soft part sarcoma, unresectable alveolar soft part sarcoma